| Stereochemistry | ABSOLUTE |
| Molecular Formula | C60H74N12O10 |
| Molecular Weight | 1123.304 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]3(CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC4=CNC5=C4C=CC=C5)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)CCCNC(=O)CCCN(CC(N)=O)C(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@@]([H])(NC(=O)[C@H](CCCCN)NC3=O)[C@@H](C)O
InChI
InChIKey=ABFNTRQPWNXUHA-VEVJRHMJSA-N
InChI=1S/C60H74N12O10/c1-37(73)54-59(81)70-50(31-39-18-6-3-7-19-39)60(82)72(36-51(62)74)29-15-26-52(75)63-28-14-25-53(76)66-47(30-38-16-4-2-5-17-38)56(78)68-49(33-41-35-65-45-23-11-9-21-43(41)45)58(80)69-48(32-40-34-64-44-22-10-8-20-42(40)44)57(79)67-46(55(77)71-54)24-12-13-27-61/h2-11,16-23,34-35,37,46-50,54,64-65,73H,12-15,24-33,36,61H2,1H3,(H2,62,74)(H,63,75)(H,66,76)(H,67,79)(H,68,78)(H,69,80)(H,70,81)(H,71,77)/t37-,46+,47+,48-,49+,50+,54+/m1/s1
Somatoprim (DG3173) is a heptapeptide somatostatin analog (SSA) that binds with high affinity to sstr2, sstr4 and sstr5 and shows a very low insulin suppression in contrast to other SSA. Initially developed by Ipsen, it is under active development by licensee Aspireo Pharmaceuticals, an Israeli company.
In vitro as well as in vivo testing showed a dose-dependent GH lowering effect. Somatoprim has demonstrated a unique receptor binding and pharmacological profile which is differentiated from SSAs that are currently marketed or in clinical development. In particular, Somatoprim has shown an improved side effect profile with reduced adverse effects on the gastrointestinal tract and glucose metabolism. Furthermore, assessment of growth hormone secretion in cultured human somatotroph adenoma tissue treated with Somatoprim indicates that it has the potential to increase the response rate of acromegalic patients to SSA therapy. Somatoprim is currently in phase I/II of clinical development.
Originator
Approval Year
PubMed
Sample Use Guides
Acromegaly: octreotide and Somatoprim (DG3173). Eligible patients are to receive 300 ug octreotide as active comparator, followed by four ascending doses of 100 ug, 300 ug, 900 ug and 1800 ug DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
Route of Administration:
Other
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
